테보젠 바이오 홀딩스(TVGN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $6.87 (+4.57%), 시가총액 $0.04B, 52주 범위 $0.19 ~ $9.42.
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in p
테보젠 바이오 홀딩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
테보젠 바이오 홀딩스의 현재 주가는 $6.87 (+4.57%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
테보젠 바이오 홀딩스의 시가총액은 약 $0.04B입니다.
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders.